Ozempic cuts kidney-disease risks, research finds
Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in...
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed re...
Novo Nordisk weight loss drugs still showing upside risk - analyst
Novo Nordisk (NYSE:NVO) A/S' weight loss drug rollout continues to offer scope for upside surprises, Citi analysts have said. Despite ongoing supply constraints, four-week rolling prescription grow...
Is Novo Nordisk Stock a Millionaire Maker?
Novo Nordisk's already strong financials could look even better in the future as the company's drugs have loads of potential. The company's high-profit margins make it likely that earnings will soa...
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
No prizes for guessing which hugely popular weight loss drug has driven its growth. Determined competition is on the way, but the Danish pharmaceutical star will have defensive advantages.
Novo Nordisk owner buys majority stake in Austrian life science tools company
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it would buy a controlling stake of about 60% in Single Use Support, an Austria-based life sc...
No shortage of Wegovy weight-loss drug in Denmark, Novo Nordisk says
Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency of strained supply of two separate doses in the coming we...
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
Weight loss wonder drug reduces chance of heart attack and stroke by a fifth
Weight loss jabs Wegovy, Ozempic, and Rybelsus could lower the risk of heart attacks, strokes, or heart failure in obese individuals, irrespective of their weight loss, according to a recent study....
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.
Novo Nordisk weight loss rollout to prompt ‘dramatic upgrades' - analysts
Novo Nordisk (NYSE:NVO) could be in line for ‘dramatic earnings upgrades' as pace builds on the rollout of its weight loss drugs, analysts say. Wegovy sales could hit 76 billion Danish Krone (US$11...
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
Wegovy is a weight-loss drug that's proving it can do more than help people lose weight. Regulators recently approved it as a treatment for reducing cardiovascular risk.
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) an...
Related Companies